Sulfisoxazole

Sulfisoxazole (Sulfafurazole) is an orally active endothelin receptor antagonist with IC50 values of 0.60 μM and 22 μM against endothelin receptor A and endothelin receptor B, respectively. Sulfisoxazole is a sulfonamide antibacterial agent with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A[1][2].

Product Specifications

CAS Number

[127-69-5]

Product Name Alternative

Sulfafurazole

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Antibiotic; Bacterial; Endothelin Receptor

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Sulfisoxazole.html

Purity

99.98

Solubility

DMSO : ≥ 150 mg/mL

Smiles

O=S(C1=CC=C(N)C=C1)(NC2=C(C)C(C)=NO2)=O

Molecular Formula

C11H13N3O3S

Molecular Weight

267.30

Precautions

H315, H319, H335

References & Citations

[1]Chan, M.F., et al., Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening. Biochem Biophys Res Commun, 1994. 201 (1) : p. 228-34.|[2]Im EJ, et al. Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat Commun. 2019 Mar 27;10 (1) :1387.|[3]Shin JM, et al. Sulfisoxazole Elicits Robust Antitumour Immune Response Along with Immune Checkpoint Therapy by Inhibiting Exosomal PD-L1. Adv Sci (Weinh) . 2022 Feb;9 (5) :e2103245. |[4]Syed H, et al. Sulfisoxazole, an endothelin receptor antagonist, protects retinal neurones from insults of ischemia/reperfusion or lipopolysaccharide. Neurochem Int. 2006 Jun;48 (8) :708-17.